- Exact Sciences maintained its full-year 2025 revenue forecast between $3.22 billion and $3.24 billion, closely aligning with the estimated $3.23 billion.
- The company expects its Screening revenue to be in the range of $2.51 billion to $2.52 billion, meeting the estimate of $2.51 billion.
- Precision Oncology revenue is forecasted at $710 million to $715 million, aligning with the estimate of $712.6 million.
- Adjusted EBITDA for fiscal year 2025 is expected to be between $395 million and $405 million.
- The 2025 adjusted EBITDA guidance includes a $75 million initial payment from a completed licensing agreement.
- Analyst recommendations currently consist of 20 buys, 3 holds, and 1 sell.
“`
Exact Sciences on Smartkarma
Analysts at Baptista Research are bullish on Exact Sciences, highlighting the company’s strong financial performance and strategic initiatives. In a report titled “Exact Sciences Reinforces Its Market Edge With Strategic Alliances & Profit Growth!”, the analysts commend the company for delivering solid performance metrics in the second quarter of 2025. Exact Sciences reported processing a record 1.3 million test results during the quarter, leading to a 16% year-over-year increase in core revenue. The analysts also note that Exact Sciences revised its financial guidance upwards, reflecting robust growth across its operations.
In another report by Baptista Research titled “Exact Sciences: Launch of Cologuard Plus to Redefine Colorectal Cancer Screening Paradigm!”, analysts express optimism about Exact Sciences‘ first quarter 2025 financial results. The company achieved robust revenue growth, strategic commercial execution, and significant advancements in their product pipeline. With a total revenue increase of 11% to $707 million, exceeding the midpoint of their guidance, Exact Sciences‘ Screening segment particularly stood out with a 14% revenue rise to $540 million. This growth was attributed to successful rescreen initiatives, enhanced commercial strategies, and the introduction of Cologuard Plus.
A look at Exact Sciences Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Exact Sciences Corp. has received varying scores across different factors based on the Smartkarma Smart Scores evaluation. With a strong momentum score of 5, the company is showing positive movement in the market, indicating potential growth opportunities. Additionally, the growth score of 3 suggests that Exact Sciences is positioned for expansion and development in the long term. While the value and resilience scores are moderate at 2, showing stability and a reasonable valuation, the lower dividend score of 1 indicates the company’s focus on reinvesting in its growth rather than distributing profits to shareholders.
Overall, based on the Smartkarma Smart Scores, Exact Sciences appears to have a favorable long-term outlook, especially in terms of momentum and growth potential. With its focus on developing a non-invasive molecular screening test for colorectal cancer, the company is positioned to benefit from the increasing importance placed on early detection and prevention in healthcare. Investors may find Exact Sciences a compelling prospect for capitalizing on market trends and advancements in medical technology.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
